3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
41
Stomach Neoplasms
2
Neoplasm Metastasis
2
HER2-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Solid Tumors
1
Recurrence
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
HER2-Positive Primary Breast Cancer
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
2
Lapatinib
2
pertuzumab
1
pazopanib
1
bemcentinib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Inflammatory Breast Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts